C2.2 Postzygotic activating variants in mapk pathway genes cause intracranial and extracranial vascular malformations that respond to targeted inhibition. (4th October 2017)

• Record Type: Journal Article
• Authors: Al-Olabi, Lara; Polubothu, Satyamaanasa; Dowsett, Katherine; Andrews, Katrina A; Stadnik, Paulina; Joseph, Agnel P; Knox, Rachel; Pittman, Alan; Clark, Graeme; Baird, William; Bulstrode, Neil; Glover, Mary; Gordon, Kristiana; Hargrave, Darren; Huson, Susan M; Jacques, Thomas; James, Gregory; Kondolf, Hannah; Kangesu, Loshan; Keppler-Noreuil, Kim M; Khan, Amjad; Lindhurst, Marjorie J; Lipson, Mark; Mansour, Sahar; O'Hara, Justine; Mahon, Caroline; Mosica, Anda; Moss, Celia; Murthy, Aditi; Ong, Juling; Parker, Victoria; Rivière, Jean-Baptiste; Sapp, Julie C; Sebire, Neil J; Shah, Rahul; Sivakumar, Bran; Thomas, Anna; Virasami, Alex; Waelchli, Regula; Zeng, Zhiqiang; Biesecker, Leslie G; Barnacle, Alex; Topf, Maja; Semple, Robert; Patton, E Elizabeth; Kinsler, Veronica A;
• Is Part Of: Archives of disease in childhood. Volume 102(2017)Supplement 3
• Page Start: A11
• Page End: A12
• Publication Date: 2017-10-04
• Subjects: Children -- Diseases -- Periodicals; Infants -- Diseases -- Periodicals; 618.920005
• DOI: 10.1136/archdischild-2017-084620.30
• Languages: English
• ISSNs: 0003-9888

Abstract

Abstract : Background: Sporadic vascular malformations (VMs) are complex congenital anomalies of blood vessels that lead to stroke, life-threatening bleeds, disfigurement, overgrowth, and/or pain. Therapeutic options are severely limited and multi-disciplinary management remains challenging, particularly for high-flow arteriovenous malformations (AVM). Project: To investigate the pathogenesis of 160 sporadic VMs in which known genetic causes had been excluded, sequencing of affected tissue DNA was undertaken using deep next generation sequencing with analysis optimised for detection of low mutant allele frequency. Results: Mosaic activating variants in KRAS, NRAS, BRAF and MAP2K1 were identified, most commonly in AVM, both intracranial and extracranial. Transgenic zebrafish expressing BRAF V600E only in the vasculature recapitulated the human phenotype. Treatment of zebrafish with the BRAF inihibitor, vemurafinib, restored blood flow in AVM. Conclusions: These findings reveal an important unifying cause of sporadic vascular malformations of different clinical types, and offer the potential of personalised medical treatment for affected individuals by repurposing of existing licensed cancer therapies.